サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1464692

ウイルスベクターおよびプラスミドDNA製造市場：ベクタータイプ別、ワークフロー別、疾患別、用途別、エンドユーザー別、国別、地域別-2024-2032年の産業分析、市場規模、市場シェア、予測

Viral Vector and Plasmid DNA Manufacturing Market, By Vector Type, By Workflow, By Disease, By Application, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 303 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
ウイルスベクターおよびプラスミドDNA製造市場：ベクタータイプ別、ワークフロー別、疾患別、用途別、エンドユーザー別、国別、地域別-2024-2032年の産業分析、市場規模、市場シェア、予測
出版日: 2024年04月01日
発行: AnalystView Market Insights
ページ情報: 英文 303 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レポートハイライト

ウイルスベクターおよびプラスミドDNA製造市場規模は2023年に56億7,398万米ドルとなり、2024年から2032年にかけてCAGR 19.61%で拡大

ウイルスベクターおよびプラスミドDNA製造市場-市場力学

遺伝子治療の進歩が市場需要を促進

新たな遺伝子治療の開発は、高品質のウイルスベクターとプラスミドDNAに大きく依存しているため、市場促進要因には遺伝子治療の進歩が含まれます。さらに、製造プロセスの向上により、ウイルスベクターやプラスミドDNAをより大規模に効率的に生産することが可能になり、コスト削減と全体的な品質向上につながった。細胞・遺伝子治療研究分野への投資の増加に伴い、市場にはウイルスベクターに対する大きな需要があります。その結果、さまざまな組織がウイルスベクターの製造プロセスの開発を加速するための資金を提供しています。例えば、2019年9月、Next Generation Manufacturing Canadaは、レンチウイルスベクターの先進的な製造プロセスの開発のため、iVexSol Canadaが率いるコンソーシアムに189万米ドルを供与しました。ベクター製造企業であるiVexSol Canadaは、先進的なLVV製造プラットフォームを開発するために複数の団体と協力しています。

ウイルスベクターおよびプラスミドDNA製造市場-主な洞察

リサーチアナリストの分析によると、世界市場は予測期間（2024-2032年）に約19.81%のCAGRで毎年成長すると予測されています。

ベクタータイプ別では、アデノ随伴ウイルスが2023年に最大の市場シェアを示すと予測されました。

ワークフロー別では、2023年には下流製造が主要タイプでした。

疾患別では、がんが2023年の主要タイプでした。

エンドユーザー別では、2023年には研究機関が主要タイプでした。

用途別では、2023年にはアンチセンス＆RNAi療法が主要タイプとなっています。

地域別では、北米が2023年の売上高でトップでした。

ウイルスベクターおよびプラスミドDNA製造市場-セグメンテーション分析：

世界のウイルスベクターおよびプラスミドDNA製造市場は、ベクタータイプ、ワークフロー、疾患、用途、エンドユーザーおよび地域に基づいてセグメント化されます。

市場はベクタータイプに基づいて6つのカテゴリーに分けられる：アデノウイルス、レトロウイルス、アデノ随伴ウイルス（AAV）、レンチウイルス、プラスミド、その他。ベクターの種類別では、アデノ随伴ウイルス（AAV）分野が2023年に最大の売上高シェアで市場をリードしました。AAVは高い需要があり、目的の部位に遺伝子を送達する精度の高さから臨床試験での利用が急速に増加しています。このような採用の増加は、整形外科や眼科の遺伝子治療の開発に関連する臨床試験が、効率性と有効性の向上を示していることに起因しています。2022年8月にSpringer誌に掲載された論文では、AAVを介した遺伝子治療により後天性難聴を予防できると述べられており、様々な治療領域でAAVの応用が拡大していることがさらに強調されています。

市場はワークフローに基づいて2つのカテゴリーに分けられる：上流製造と下流製造です。ワークフローに基づくと、臨床グレードの最終製品の研磨と精製に関わる非常に複雑な手順のため、2023年には下流処理セグメントが最大の収益シェアで市場を独占しました。臨床グレードのウイルスベクターに対する需要が高まる中、メーカーは従来のラボスケールベクター製造に伴う課題に対処するため、新規でコスト効率の高い下流工程の開発に積極的に取り組んでいます。このようなアプローチは、フェドバッチ発酵技術や遺伝子的に最適化された細胞システムと従来型および新規の精製技術を組み合わせた例などに見られるように、市場の成長を支えるものと期待されています。

ウイルスベクターおよびプラスミドDNA製造市場-地理的洞察

地理的には、この市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカの各地域に広がっています。これらの地域は、ビジネスをもたらす国によってさらに分けられます。

ウイルスベクターおよびプラスミドDNA製造市場-競合情勢：

ウイルスベクターおよびプラスミドDNA製造市場のダイナミックな状況において、企業は競争力を維持し、バイオ医薬品業界の進化する需要に対応するために多様な戦略を実施しています。技術革新を推進し、能力を拡大し、補完的な専門知識やリソースを利用する上で、提携や戦略的パートナーシップは極めて重要な役割を果たしています。企業は、遺伝子治療製品の共同開発、研究洞察の交換、製造インフラの活用を目的として、バイオ医薬品企業、学術機関、研究開発・製造受託機関（CDMO）と戦略的提携を結ぶことが多いです。さらに、研究開発（R&D）への投資は、製造技術の進歩、プロセス効率の向上、製品の品質と拡張性の改善に不可欠です。ウイルスベクターおよびプラスミドDNA製造プロセスを最適化するためには、上流および下流の処理技術、精製方法、分析技術における絶え間ない技術革新が不可欠です。さらに、製造ライフサイクルを通じて製品の品質、安全性、有効性を維持するためには、規制への適合を確保し、適正製造規範（GMP）基準を遵守することが不可欠です。

目次

第1章 ウイルスベクターおよびプラスミドDNA製造市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 ウイルスベクターおよびプラスミドDNA製造の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 ウイルスベクターおよびプラスミドDNA製造産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 ウイルスベクターおよびプラスミドDNA製造市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 ウイルスベクターおよびプラスミドDNA製造市場情勢

  • ウイルスベクターおよびプラスミド DNA製造市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 ウイルスベクターおよびプラスミドDNA製造市場- ベクタータイプ別

  • 概要
    • ベクタータイプ別セグメントシェア分析
    • アデノウイルス
    • レトロウイルス
    • アデノ随伴ウイルス（AAV）
    • レンチウイルス
    • プラスミド
    • その他

第8章 ウイルスベクターおよびプラスミドDNA製造市場- ワークフロー別

  • 概要
    • ワークフロー別セグメントシェア分析
    • 上流製造
    • 下流製造

第9章 ウイルスベクターおよびプラスミドDNA製造市場- 疾患別

  • 概要
    • 疾患別セグメントシェア分析
    • がん
    • 遺伝性疾患
    • 感染症
    • その他

第10章 ウイルスベクターおよびプラスミドDNA製造市場- 用途別

  • 概要
    • 用途別セグメントシェア分析
    • アンチセンスおよびRNAi療法
    • 遺伝子治療
    • 細胞療法
    • ワクチン学
    • 調査

第11章 ウイルスベクターおよびプラスミドDNA製造市場- エンドユーザー別

  • 概要
    • エンドユーザー別セグメントシェア分析
    • 製薬・バイオ医薬品企業
    • 調査機関

第12章 ウイルスベクターおよびプラスミドDNA製造市場-地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第13章 主要ベンダー分析- ウイルスベクターおよびプラスミドDNA製造業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Merck KGaA
    • Lonza
    • FUJIFILM Diosynth Biotechnologies
    • Thermo Fisher Scientific
    • Cobra Biologics
    • Catalent Inc.
    • Wuxi Biologics
    • Takara Bio Inc.
    • Waisman Biomanufacturing
    • Genezen laboratories
    • Batavia Biosciences
    • Miltenyi Biotec GmbH
    • SIRION Biotech GmbH
    • Virovek Incorporation
    • Others

第14章 アナリストの全方位展望

図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Viral Vector and Plasmid DNA Manufacturing Market: Vector Type Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Vector Type
  • TABLE Global Viral Vector and Plasmid DNA Manufacturing Market, by Vector Type 2019-2032 (USD Million)
  • TABLE Viral Vector and Plasmid DNA Manufacturing Market: Workflow Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Workflow
  • TABLE Global Viral Vector and Plasmid DNA Manufacturing Market, by Workflow 2019-2032 (USD Million)
  • TABLE Viral Vector and Plasmid DNA Manufacturing Market: Disease Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Disease
  • TABLE Global Viral Vector and Plasmid DNA Manufacturing Market, by Disease 2019-2032 (USD Million)
  • TABLE Viral Vector and Plasmid DNA Manufacturing Market: Application Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Application
  • TABLE Global Viral Vector and Plasmid DNA Manufacturing Market, by Application 2019-2032 (USD Million)
  • TABLE Viral Vector and Plasmid DNA Manufacturing Market: End User Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by End User
  • TABLE Global Viral Vector and Plasmid DNA Manufacturing Market, by End User 2019-2032 (USD Million)
  • TABLE Viral Vector and Plasmid DNA Manufacturing Market: Regional snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Viral Vector and Plasmid DNA Manufacturing Market, by Region 2019-2032 (USD Million)
  • TABLE North America Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019-2032 (USD Million)
  • TABLE North America Viral Vector and Plasmid DNA Manufacturing Market, by Vector Type, 2019-2032 (USD Million)
  • TABLE North America Viral Vector and Plasmid DNA Manufacturing Market, by Workflow, 2019-2032 (USD Million)
  • TABLE North America Viral Vector and Plasmid DNA Manufacturing Market, by Disease, 2019-2032 (USD Million)
  • TABLE North America Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2019-2032 (USD Million)
  • TABLE North America Viral Vector and Plasmid DNA Manufacturing Market, by End User, 2019-2032 (USD Million)
  • TABLE Europe Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019-2032 (USD Million)
  • TABLE Europe Viral Vector and Plasmid DNA Manufacturing Market, by Vector Type, 2019-2032 (USD Million)
  • TABLE Europe Viral Vector and Plasmid DNA Manufacturing Market, by Workflow, 2019-2032 (USD Million)
  • TABLE Europe Viral Vector and Plasmid DNA Manufacturing Market, by Disease, 2019-2032 (USD Million)
  • TABLE Europe Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2019-2032 (USD Million)
  • TABLE Europe Viral Vector and Plasmid DNA Manufacturing Market, by End User, 2019-2032 (USD Million)
  • TABLE Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019-2032 (USD Million)
  • TABLE Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Vector Type, 2019-2032 (USD Million)
  • TABLE Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Workflow, 2019-2032 (USD Million)
  • TABLE Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Disease, 2019-2032 (USD Million)
  • TABLE Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2019-2032 (USD Million)
  • TABLE Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by End User, 2019-2032 (USD Million)
  • TABLE Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019-2032 (USD Million)
  • TABLE Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Vector Type, 2019-2032 (USD Million)
  • TABLE Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Workflow, 2019-2032 (USD Million)
  • TABLE Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Disease, 2019-2032 (USD Million)
  • TABLE Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2019-2032 (USD Million)
  • TABLE Latin America Viral Vector and Plasmid DNA Manufacturing Market, by End User, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Vector Type, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Workflow, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Disease, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by End User, 2019-2032 (USD Million)
目次
Product Code: ANV2452

REPORT HIGHLIGHT

Viral Vector and Plasmid DNA Manufacturing Market size was valued at USD 5,673.98 Million in 2023, expanding at a CAGR of 19.61% from 2024 to 2032.

The Viral Vector and Plasmid DNA Manufacturing sector represents a vital segment within the biopharmaceutical industry, dedicated to producing viral vectors and plasmid DNA for gene therapy and vaccine development purposes. Viral vectors are genetically engineered viruses used to transport therapeutic genes into target cells, while plasmid DNA serves as a critical component in gene therapy and DNA vaccine production. This market significantly contributes to advancing medical treatments by facilitating the development of innovative therapies for a broad spectrum of genetic disorders, infectious diseases, and cancers. Given the rapid progress in biotechnology and the increasing investment in gene therapy research, the demand for viral vectors and plasmid DNA manufacturing continues to steadily rise. This growth is fueled by factors such as the increasing prevalence of genetic diseases, the expanding pipeline of gene therapy candidates, and the growing adoption of personalized medicine approaches.

Viral Vector and Plasmid DNA Manufacturing Market- Market Dynamics

Advancements in gene therapy to propel market demand

The primary drivers of the market include advancements in gene therapy, as the development of new gene therapies heavily relies on high-quality viral vectors and plasmid DNA. Moreover, enhancements in manufacturing processes have enabled more efficient production of viral vectors and plasmid DNA at larger scales, leading to cost reductions and improved overall quality. With increased investments in the cell and gene therapy research space, there is significant demand for viral vectors in the market. Consequently, various organizations are providing funds to accelerate developments in manufacturing processes for viral vectors. For instance, in September 2019, Next Generation Manufacturing Canada granted USD 1.89 million to a consortium led by iVexSol Canada for the development of an advanced manufacturing process for lentiviral vectors. iVexSol Canada, a vector manufacturing company, has collaborated with several entities to develop an advanced LVV manufacturing platform.

Viral Vector and Plasmid DNA Manufacturing Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 19.81% over the forecast period (2024-2032)

Based on Vector Type segmentation, adeno-associated virus was predicted to show maximum market share in the year 2023

Based on Workflow segmentation, downstream processing was the leading type in 2023

Based on Disease segmentation, Cancer was the leading type in 2023

Based on end user segmentation, research institute was the leading type in 2023

Based on Application segmentation, Antisense & RNAi Therapy was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Viral Vector and Plasmid DNA Manufacturing Market- Segmentation Analysis:

The Global Viral Vector and Plasmid DNA Manufacturing Market is segmented on the basis of Vector Type, Workflow, Disease, Application, End User and Region.

The market is divided into six categories based on vector type: Adenovirus, Retrovirus, Adeno-Associated Virus (AAV), Lentivirus, Plasmids and Others. In terms of vector type, the adeno-associated virus (AAV) segment led the market with the largest revenue share in 2023. AAVs are in high demand, with their utilization in clinical trials increasing rapidly due to their precision in delivering genes to the region of interest. This rising adoption is attributed to clinical trials related to the development of orthopedic and ocular gene therapies demonstrating increased efficiency and efficacy. An article published in Springer in August 2022 stated that AAV-mediated gene therapy could prevent acquired hearing loss, further highlighting the expanding applications of AAV across various therapeutic areas.

The market is divided into two categories based on Workflow: Upstream Manufacturing and Downstream Manufacturing. Based on the workflow, the downstream processing segment dominated the market in 2023 with the largest revenue share, owing to highly complex procedures involved in polishing and purifying clinical-grade final products. With the growing demand for clinical-grade viral vectors, manufacturers are actively engaged in developing novel, cost-effective downstream processes to address challenges associated with conventional lab-scale vector manufacturing. This approach is expected to support market growth, as seen in examples such as combining fed-batch fermentation techniques and genetically optimized cell systems with conventional and novel purification technologies.

Viral Vector and Plasmid DNA Manufacturing Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Viral Vector and Plasmid DNA Manufacturing Market- Competitive Landscape:

In the dynamic landscape of the Viral Vector and Plasmid DNA Manufacturing market, companies implement diverse strategies to uphold competitiveness and address the evolving demands of the biopharmaceutical industry. Collaboration and strategic partnerships play a crucial role in driving innovation, expanding capabilities, and accessing complementary expertise and resources. Companies frequently establish strategic alliances with biopharmaceutical firms, academic institutions, and contract development and manufacturing organizations (CDMOs) to co-develop gene therapy products, exchange research insights, and utilize manufacturing infrastructure. Moreover, investments in research and development (R&D) are essential for advancing manufacturing technologies, enhancing process efficiency, and improving product quality and scalability. Continuous innovation in upstream and downstream processing techniques, purification methods, and analytical technologies is vital for optimizing viral vector and plasmid DNA production processes. Additionally, ensuring regulatory compliance and adhering to Good Manufacturing Practices (GMP) standards are imperative for maintaining product quality, safety, and efficacy throughout the manufacturing lifecycle.

Recent Developments:

In October 2023, AGC Biologics revealed plans for the expansion of their plasmid DNA (pDNA) manufacturing facility located in Germany. This strategic move is anticipated to enable the company to decrease manufacturing time.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Merck KGaA

Lonza

FUJIFILM Diosynth Biotechnologies

Thermo Fisher Scientific

Cobra Biologics

Catalent Inc.

Wuxi Biologics

Takara Bio Inc.

Waisman Biomanufacturing

Genezen laboratories

Batavia Biosciences

Miltenyi Biotec GmbH

SIRION Biotech GmbH

Virovek Incorporation

Others

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE- MARKET ANALYSIS, 2019 - 2032

  • Adenovirus
  • Retrovirus
  • Adeno-Associated Virus (AAV)
  • Lentivirus
  • Plasmids
  • Others

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW- MARKET ANALYSIS, 2019 - 2032

  • Upstream Manufacturing
  • Downstream Manufacturing

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE- MARKET ANALYSIS, 2019 - 2032

  • Cancer
  • Genetic Disorders
  • Infectious Diseases
  • Others

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Antisense & RNAi Therapy
  • Gene Therapy
  • Cell Therapy
  • Vaccinology
  • Research Applications

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1.Viral Vector and Plasmid DNA Manufacturing Market Overview

  • 1.1.Study Scope
  • 1.2.Market Estimation Years

2.Executive Summary

  • 2.1.Market Snippet
    • 2.1.1.Viral Vector and Plasmid DNA Manufacturing Market Snippet by Vector Type
    • 2.1.2.Viral Vector and Plasmid DNA Manufacturing Market Snippet by Workflow
    • 2.1.3.Viral Vector and Plasmid DNA Manufacturing Market Snippet by Disease
    • 2.1.4.Viral Vector and Plasmid DNA Manufacturing Market Snippet by Application
    • 2.1.5.Viral Vector and Plasmid DNA Manufacturing Market Snippet by End User
    • 2.1.6.Viral Vector and Plasmid DNA Manufacturing Market Snippet by Country
    • 2.1.7.Viral Vector and Plasmid DNA Manufacturing Market Snippet by Region
  • 2.2.Competitive Insights

3.Viral Vector and Plasmid DNA Manufacturing Key Market Trends

  • 3.1.Viral Vector and Plasmid DNA Manufacturing Market Drivers
    • 3.1.1.Impact Analysis of Market Drivers
  • 3.2.Viral Vector and Plasmid DNA Manufacturing Market Restraints
    • 3.2.1.Impact Analysis of Market Restraints
  • 3.3.Viral Vector and Plasmid DNA Manufacturing Market Opportunities
  • 3.4.Viral Vector and Plasmid DNA Manufacturing Market Future Trends

4.Viral Vector and Plasmid DNA Manufacturing Industry Study

  • 4.1.PEST Analysis
  • 4.2.Porter's Five Forces Analysis
  • 4.3.Growth Prospect Mapping
  • 4.4.Regulatory Framework Analysis

5.Viral Vector and Plasmid DNA Manufacturing Market: COVID-19 Impact Analysis

  • 5.1.Pre-COVID-19 Impact Analysis
  • 5.2.Post-COVID-19 Impact Analysis
    • 5.2.1.Top Performing Segments
    • 5.2.2.Marginal Growth Segments
    • 5.2.3.Top Looser Segments
    • 5.2.4.Marginal Loss Segments

6.Viral Vector and Plasmid DNA Manufacturing Market Landscape

  • 6.1.Viral Vector and Plasmid DNA Manufacturing Market Share Analysis, 2023
  • 6.2.Breakdown Data, by Key Manufacturer
    • 6.2.1.Established Players' Analysis
    • 6.2.2.Emerging Players' Analysis

7.Viral Vector and Plasmid DNA Manufacturing Market - By Vector Type

  • 7.1.Overview
    • 7.1.1.Segment Share Analysis, By Vector Type, 2023 & 2032 (%)
    • 7.1.2.Adenovirus
    • 7.1.3.Retrovirus
    • 7.1.4.Adeno-Associated Virus (AAV)
    • 7.1.5.Lentivirus
    • 7.1.6.Plasmids
    • 7.1.7.Others

8.Viral Vector and Plasmid DNA Manufacturing Market - By Workflow

  • 8.1.Overview
    • 8.1.1.Segment Share Analysis, By Workflow, 2023 & 2032 (%)
    • 8.1.2.Upstream Manufacturing
    • 8.1.3.Downstream Manufacturing

9.Viral Vector and Plasmid DNA Manufacturing Market - By Disease

  • 9.1.Overview
    • 9.1.1.Segment Share Analysis, By Disease, 2023 & 2032 (%)
    • 9.1.2.Cancer
    • 9.1.3.Genetic Disorders
    • 9.1.4.Infectious Diseases
    • 9.1.5.Others

10.Viral Vector and Plasmid DNA Manufacturing Market - By Application

  • 10.1.Overview
    • 10.1.1.Segment Share Analysis, By Application, 2023 & 2032 (%)
    • 10.1.2.Antisense & RNAi Therapy
    • 10.1.3.Gene Therapy
    • 10.1.4.Cell Therapy
    • 10.1.5.Vaccinology
    • 10.1.6.Research Applications

11.Viral Vector and Plasmid DNA Manufacturing Market - By End User

  • 11.1.Overview
    • 11.1.1.Segment Share Analysis, By End User, 2023 & 2032 (%)
    • 11.1.2.Pharmaceutical and Biopharmaceutical Companies
    • 11.1.3.Research Institutes

12.Viral Vector and Plasmid DNA Manufacturing Market- By Geography

  • 12.1.Introduction
    • 12.1.1.Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 12.2.North America
    • 12.2.1.Overview
    • 12.2.2.Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in North America
    • 12.2.3.North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4.North America Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.2.5.North America Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.2.6.North America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.2.7.North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.2.8.North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.9.U.S.
      • 12.2.9.1.Overview
      • 12.2.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3.U.S. Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.2.9.4.U.S. Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.2.9.5.U.S. Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.2.9.6.U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.2.9.7.U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.10.Canada
      • 12.2.10.1.Overview
      • 12.2.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3.Canada Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.2.10.4.Canada Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.2.10.5.Canada Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.2.10.6.Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.2.10.7.Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3.Europe
    • 12.3.1.Overview
    • 12.3.2.Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in Europe
    • 12.3.3.Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4.Europe Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.3.5.Europe Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.3.6.Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.3.7.Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.8.Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.9.Germany
      • 12.3.9.1.Overview
      • 12.3.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3.Germany Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.9.4.Germany Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.9.5.Germany Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.3.9.6.Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.9.7.Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.10.Italy
      • 12.3.10.1.Overview
      • 12.3.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3.Italy Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.10.4.Italy Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.10.5.Italy Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.3.10.6.Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.10.7.Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.11.United Kingdom
      • 12.3.11.1.Overview
      • 12.3.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3.United Kingdom Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.11.4.United Kingdom Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.11.5.United Kingdom Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.3.11.6.United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.11.7.United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.12.France
      • 12.3.12.1.Overview
      • 12.3.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3.France Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.12.4.France Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.12.5.France Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.3.12.6.France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.12.7.France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.13.Russia
      • 12.3.13.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.2.Russia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.13.3.Russia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.13.4.Russia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.3.13.5.Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.13.6.Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.14.Netherlands
      • 12.3.14.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.2.Netherlands Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.14.3.Netherlands Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.14.4.Netherlands Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.3.14.5.Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.14.6.Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.15.Sweden
      • 12.3.15.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.2.Sweden Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.15.3.Sweden Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.15.4.Sweden Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.3.15.5.Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.15.6.Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.16.Poland
      • 12.3.16.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.2.Poland Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.16.3.Poland Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.16.4.Poland Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.3.16.5.Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.16.6.Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.17.Rest of Europe
      • 12.3.17.1.Overview
      • 12.3.17.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3.Rest of the Europe Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.17.4.Rest of the Europe Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.17.5.Rest of the Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.3.17.6.Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.17.7.Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4.Asia Pacific (APAC)
    • 12.4.1.Overview
    • 12.4.2.Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in Asia Pacific
    • 12.4.3.Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4.Asia Pacific Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.4.5.Asia Pacific Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.4.6.Asia Pacific Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.4.7.Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.8.Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.9.India
      • 12.4.9.1.Overview
      • 12.4.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3.India Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.9.4.India Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.9.5.India Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.4.9.6.India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.9.7.India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.10.China
      • 12.4.10.1.Overview
      • 12.4.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3.China Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.10.4.China Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.10.5.China Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.4.10.6.China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.10.7.China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.11.Japan
      • 12.4.11.1.Overview
      • 12.4.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3.Japan Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.11.4.Japan Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.11.5.Japan Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.4.11.6.Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.11.7.Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.12.South Korea
      • 12.4.12.1.Overview
      • 12.4.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3.South Korea Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.12.4.South Korea Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.12.5.South Korea Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.4.12.6.South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.12.7.South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.13.Australia
      • 12.4.13.1.Overview
      • 12.4.13.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3.Australia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.13.4.Australia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.13.5.Australia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.4.13.6.Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.13.7.Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.14.Thailand
      • 12.4.14.1.Overview
      • 12.4.14.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3.Thailand Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.14.4.Thailand Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.14.5.Thailand Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.4.14.6.Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.14.7.Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.15.Indonesia
      • 12.4.15.1.Overview
      • 12.4.15.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3.Indonesia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.15.4.Indonesia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.15.5.Indonesia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.4.15.6.Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.15.7.Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.16.Philippines
      • 12.4.16.1.Overview
      • 12.4.16.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3.Philippines Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.16.4.Philippines Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.16.5.Philippines Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.4.16.6.Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.16.7.Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.17.Rest of APAC
      • 12.4.17.1.Overview
      • 12.4.17.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3.Rest of APAC Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.17.4.Rest of APAC Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.17.5.Rest of APAC Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.4.17.6.Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.17.7.Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.5.Latin America
    • 12.5.1.Overview
    • 12.5.2.Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in Latin America
    • 12.5.3.Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4.Latin America Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.5.5.Latin America Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.5.6.Latin America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.5.7.Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.8.Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.9.Brazil
      • 12.5.9.1.Overview
      • 12.5.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3.Brazil Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.5.9.4.Brazil Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.5.9.5.Brazil Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.5.9.6.Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.9.7.Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.10.Mexico
      • 12.5.10.1.Overview
      • 12.5.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3.Mexico Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.5.10.4.Mexico Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.5.10.5.Mexico Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.5.10.6.Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.10.7.Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.11.Argentina
      • 12.5.11.1.Overview
      • 12.5.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3.Argentina Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.5.11.4.Argentina Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.5.11.5.Argentina Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.5.11.6.Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.11.7.Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.12.Colombia
      • 12.5.12.1.Overview
      • 12.5.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3.Colombia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.5.12.4.Colombia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.5.12.5.Colombia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.5.12.6.Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.12.7.Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.13.Rest of LATAM
      • 12.5.13.1.Overview
      • 12.5.13.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3.Rest of LATAM Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.5.13.4.Rest of LATAM Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.5.13.5.Rest of LATAM Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.5.13.6.Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.13.7.Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6.Middle East and Africa
    • 12.6.1.Overview
    • 12.6.2.Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in Middle East and Africa
    • 12.6.3.Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4.Middle East and Africa Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.6.5.Middle East and Africa Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.6.6.Middle East and Africa Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.6.7.Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.8.Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.9.Saudi Arabia
      • 12.6.9.1.Overview
      • 12.6.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3.Saudi Arabia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.9.4.Saudi Arabia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.9.5.Saudi Arabia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.6.9.6.Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.9.7.Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.10.United Arab Emirates
      • 12.6.10.1.Overview
      • 12.6.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3.United Arab Emirates Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.10.4.United Arab Emirates Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.10.5.United Arab Emirates Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.6.10.6.United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.10.7.United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.11.Israel
      • 12.6.11.1.Overview
      • 12.6.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3.Israel Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.11.4.Israel Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.11.5.Israel Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.6.11.6.Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.11.7.Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.12.Turkey
      • 12.6.12.1.Overview
      • 12.6.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3.Turkey Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.12.4.Turkey Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.12.5.Turkey Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.6.12.6.Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.12.7.Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.13.Algeria
      • 12.6.13.1.Overview
      • 12.6.13.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3.Algeria Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.13.4.Algeria Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.13.5.Algeria Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.6.13.6.Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.13.7.Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.14.Egypt
      • 12.6.14.1.Overview
      • 12.6.14.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3.Egypt Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.14.4.Egypt Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.14.5.Egypt Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.6.14.6.Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.14.7.Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.15.Rest of MEA
      • 12.6.15.1.Overview
      • 12.6.15.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3.Rest of MEA Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.15.4.Rest of MEA Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.15.5.Rest of MEA Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 12.6.15.6.Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.15.7.Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

13.Key Vendor Analysis- Viral Vector and Plasmid DNA Manufacturing Industry

  • 13.1.Competitive Dashboard
  • 13.2.Company Profiles
    • 13.2.1.Merck KGaA
    • 13.2.2.Lonza
    • 13.2.3.FUJIFILM Diosynth Biotechnologies
    • 13.2.4.Thermo Fisher Scientific
    • 13.2.5.Cobra Biologics
    • 13.2.6.Catalent Inc.
    • 13.2.7.Wuxi Biologics
    • 13.2.8.Takara Bio Inc.
    • 13.2.9.Waisman Biomanufacturing
    • 13.2.10.Genezen laboratories
    • 13.2.11.Batavia Biosciences
    • 13.2.12.Miltenyi Biotec GmbH
    • 13.2.13.SIRION Biotech GmbH
    • 13.2.14.Virovek Incorporation
    • 13.2.15.Others

14.360 Degree Analyst View

15.Appendix

  • 15.1.Research Methodology
  • 15.2.References
  • 15.3.Abbreviations
  • 15.4.Disclaimer
  • 15.5.Contact Us